Astria Therapeutics Inc [ATXS] stock is trading at $13.09, up 0.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ATXS shares have gain 1.47% over the last week, with a monthly amount glided 3.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Astria Therapeutics Inc [NASDAQ: ATXS] stock has seen the most recent analyst activity on November 12, 2025, when Cantor Fitzgerald downgraded its rating to a Neutral. Previously, H.C. Wainwright reaffirmed its Buy rating on September 17, 2025, and elevated its price target to $20. On April 29, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $47 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $26 on January 31, 2025. TD Cowen initiated its recommendation with a Buy and recommended $35 as its price target on July 29, 2024. Evercore ISI started tracking with a Outperform rating for this stock on March 28, 2023, and assigned it a price target of $18.
Astria Therapeutics Inc [ATXS] stock has fluctuated between $3.56 and $13.29 over the past year. Currently, Wall Street analysts expect the stock to reach $17.33 within the next 12 months. Astria Therapeutics Inc [NASDAQ: ATXS] shares were valued at $13.09 at the most recent close of the market. An investor can expect a potential return of 32.39% based on the average ATXS price forecast.
Analyzing the ATXS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.39 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.00 points at the first support level, and at 12.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.16, and for the 2nd resistance point, it is at 13.22.
Ratios To Look Out For
For context, Astria Therapeutics Inc’s Current Ratio is 10.78. As well, the Quick Ratio is 10.78, while the Cash Ratio is 4.23. Considering the valuation of this stock, the price to sales ratio is 1052.45, the price to book ratio is 5.36.
